Los pacientes tratados con CMP/UMP recobran la función neurológica alterada y experimentan una disminución de dolor, por lo que resulta de interés la investigación del posible efecto de CMP/UMP en la fatiga. La administración del fármaco Nucleo C.M.P Forte (CMP/UMP) compuesto por dos nucleótidos, citosina monofosfato (CMP) y uridina monofosfato (UMP), se utiliza en el tratamiento de afecciones neuromusculares en humanos. La causa de la fatiga muscular no está bien comprendida. These results suggest that administration of CMP/UMP enable rats to endure exercise by altering some metabolic parameters. Lactate dehydrogenase and aspartate aminotransferase activity is significantly lower in the liver of treated rats. Liver glycogen levels remains unaltered during exercise, suggesting that CMP/UMP may be implicated in maintaining the level of hepatic glycogen constant during exercise. Before exercise, muscle glucose level is significantly higher in treated rats, suggesting that the administration of CMP/UMP favours the entry of glucose in the muscle. Our results show that rats treated with CMP/UMP are able to endure longer periods of exercise (treadmill-run). With such aim, we have determined, in exercised rats treated with CMP/UMP, exercise endurance, levels of lactate, glucose and glycogen, and the activity of several metabolic enzymes such as, creatine kinase (CK), lactate dehydrogenase (LDH), and aspartate aminotransferase (AST). Patients treated with CMP/UMP recover from altered neurological functions and experience pain relief, thus the interest to investigate the possible effect of the drug on exhausting exercise. Administration of two nucleotides, cytosine monophosphate (CMP) and uridine monophosphate (UMP), has been prescribed for the treatment of neuromuscular affections in humans. The aetiology of muscle fatigue has yet not been clearly established.
0 Comments
Leave a Reply. |